Coordination of Data and Incentives to drive AMR progress: a US perspective


Michael Bell, MD

Centers for Disease Control and Prevention

Division of Healthcare Quality Promotion



Antibiotic Resistance Old Challenge, New Opportunity



Keeping pace with a Complex System



Hospitals

Dialysis facilities

Ambulatory facilities

Long-term care



Making Health Care Safer



rough partial, modulal lane can each action decreases called hand new amortists of decreases (IdAda). While most types of HAda et declinate, Gan-council by the grean of the partial control of the grean void. C. difficult course distribution has been a void. C. difficult course distribution to train as proposed, sepecially often robbs, then the partial course of the partial course of the train as periors that anotherine, rote depression at poster against infection are destroyed than a periors that anotherine, rote of green and poster against infection are destroyed and control of the partial course of the course of the course of the partial course of the course of addition of the proper in the state of the course of difficult antertown for the over yrapismum in comparison of the proper recently cared or in declarary offices and claims. C. difficult or in declarary offices and claims. C. difficult fections cout a faster has habit


"therefore again (see 1990 acres 1997 and)

To learn more about how to stop the spread

man of against the against a



Regional control of Carbapemen-resistant Enterobacteriaceae (CRE)




Timely Data + Effective Policies | Impact



- National Healthcare Safety Network (NHSN)
 - Web-based system for US hospitals to send healthcare outcomes data to CDC and State health departments
- US Centers for Medicare and Medicaid Services (CMS)
 - National healthcare reimbursement policies require hospitals to send data to CDC
 - Payment is now adjusted based on data reported to NHSN
- Non-punitive opportunities + resources for improvement
 - Technical assistance from CDC and State health departments
 - **CMS-supported Quality Improvement Networks**
 - **Accreditation Organizations**

US National Healthcare Safety Network (NHSN) NHSN Healthcare **Patient** Long-term Personnel **Bio-vigilance** Dialysis **Safety** Care (Blood and Safety Component Tissues) Procedure-Device-**Associated Associated** MDRO/CDI **Antimicrobial Infections Infections Use and** Resistance **Antimicrobial Antimicrobial Use** Resistance

Increasing Transparency: CDC data for State and Federal initiatives



NEW MEXICO HEALTHCARE-ASSOCIATED INFECTIONS ANNUAL REPORT

Healthcare-associated infection prevention in New Mexico

Heathrcare-associated infections (HA) are intections patients can acquire writer receiving medical freatment. The New Mexico (Department of Health (NIMDOH) and New Mexico (NM) HAI Advisory Committee have facilitated statewide and regional HAI prevention efforts since 2008. NIMDOH receives both victurary and mandatory data from healthcare facilities and publishes an annual surveillance report.

This annual report provides an update on NM HAI prevention progress in 2013. This aims report provides an appare of rew his prevention progress in 2015. Facility-specific information is on the NMDOH website (http://mmhealth.org/go/hai) for hospitals reporting to NMDOH. Additional detail on methodology and infections can be found in the NM HAI Annual Report 2012 (http://mmhealth.org/go/hai). Statespecific 2012 data for all states is included in the Centers for Disease Control and Prevention (CDC) 2012 HAI Progress Report (www.cdc.gov/hai/progress-report/) and Hospital Compare (www.medicare.gov/ho safety data on additional facilities in NM and nationally.

compares the current number of infections to the number of predicted infections based on national baseline data; lower SIRs indicate better progress (i.e., fewer infections). National prevention targets are set by US Department of Health and intections), National prevention targets are set by Us Department of Health and Human Services (HHS) and through the Healthy People (HP) Timmwork: Infection data are collected through CDC's National Healthcare Safety Network (NHSN) data-base. HAI data provide healthcare facilities and public health agencies information needed to design, implement, monitor, and evaluate HAI prevention efforts.

2013 New Mexico key findings

- . Central line-associated bloodstream infection SIR met the national 2013 HHS prevention target
- Healthcare personnel influenza vaccination rate was better than the
- but did not meet the 2013 HHS target Facility-onset methicillin-resistant Staphylococcus aureus SIR was better than the 2013 HHS target

Page 2 & 3: NM progress on CLABSI, CDI, MRSA. and HCP influenza vaccination

Central line-associated bloodstream infection (CLABSI)* - A central line is a tube placed in a large blood ves-sel usually of a patient's neck or chest for giving medications,



Predicted

Infections

(B)

15.230

Standardized

Infection Ratio (SIR)

(A/B)

1.313

Evaluat

than U.S

National Benchm

HOSPITAL NMC Available⁵ Available Available Available MEDSTAR 13 9769 24.425 0.532 Retter than the GEORGETOWN U.S. National UNIVERSITY Benchmark HOSPITAL



Standardized infection ratio (SIR) national benchmark = 1. Lower SIRs are better. A score of (0) - meaning no CLABSIs - is best.

▼ Table 1 of 6 Central line-associated blood stream infections (CLABSI)

Central

Line

Days

6983

(CLDs)

No. of

(A)

GEORGE

HOSPITAL

WASHINGTON UNIV

Infections

Reported

Data for Action: Targeted Assessment for Prevention (TAP)

CDC Data


Rank Hospitals by Outcome

Contact hospitals with excessive outcomes of interest

Technical Assistance

- Quality Improvement organizations
- State Health Departments
- Other partners

Demonstrating Preventability of Healthcare-associated Infections (HAI)



*CLABSI: Central line-associated bloodstream infections †MRSA: Methicillin-resistant Staphylococcus aureus


Public Health & Clinical Laboratory data

Complementary roles:

- Clinical testing for patient-care decisions and contributing to regional and national data
- State Public Health testing to inform both clinical and local public health decision-making (e.g., outbreak identification)
- CDC reference testing, esoteric testing, providing national data for local, regional & national interventions

Accurate, reliable laboratory data are essential for AMR control.

Improving Antibiotic Use: Stewardship Programs in Hospitals



Division of Healthcare Quality Promotion

Want to learn more? Vi sit

- 7 Key Elements
- Leadership commitment
- Accountability
- □ Drug expertise
- □ Action
- □ Tracking
- Reporting
- Education

Antimicrobial Use Data

- Monthly data--required for:
 - 1. Critical care medical and surgical critical care units
 - 2. Ward medical and surgical wards
 - 3. Specialty care area e.g., oncology, dialysis
 - 4. Facility-wide All inpatient locations
- Numerator: Antimicrobial days (days of therapy)
 - 86 antimicrobials collected includes antibacterial, antifungal, and antiinfluenza agents
 - Agents are sub-stratified by route of administration: intravenous (IV), intramuscular (IM), digestive (oral), and respiratory (inhaled)
- Denominators:
 - Days Present number of patients present for any portion of each day of a calendar month in specific unit or in any inpatient location (facility-wide)
 - Admissions number of patients admitted to the facility (facility-wide calculation only)

Rate Table for Facility-Wide AU

National Healthcare Safety Network

Rate Table - Most Recent Month of AU Data - Antimicrobial Utilization Rates for FACWIDEIN

Rate per 1,000 Days Present

As of: February 23, 2015 at 1:44 PM
Date Range: All AU_RATES1MONTHFACWIDEIN

Facility Org ID=13860


Summary Year/Month	Antimicrobial Category	Antimicrobial Class	Antimicrobial Days	Days Present	Rate per 1000 Days Present
2015M01	Antibacterial	All	1626	2177	746.899
2015M01	Antibacterial	Aminoglycosides	22	2177	10.106
2015M01	Antibacterial	Carbapenems	101	2177	46.394
2015M01	Antibacterial	Cephalosporins	337	2177	154.8
2015M01	Antibacterial	Fluoroquinolones	244	2177	112.081
2015M01	Antibacterial	Folate pathway inhibitors	32	2177	14.699
2015M01	Antibacterial	Folate pathway inhibitors/Sulfonamides	0	2177	0

Sample rate table for all submitted AU data by FacWidelN (all inpatient locations reporting AU data)

- Generates a rate of utilization per 1,000 days present for each antimicrobial class for all inpatient locations combined
- Report includes separate rates for each antimicrobial class for each month of data submitted

*Data for example only

AU Data - Pie Chart by Location




Sample pie chart by location

Shows proportion of antimicrobial days per antibacterial class

*Data for example only


AU Data - Bar Chart by Location



Sample bar chart by location

Shows proportion of antimicrobial days per antifungal class

Quarterly AU Data Submissions to NHSN - Current and Projected as of April 2015



National Strategy to Combat Antibiotic Resistant Bacteria, September 2014 – 5 Goals





NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA

Vision: The United States will work domestically and internationally to prevent, detect, and control illness and death related to infections caused by antibiotic-resistant bacteria by implementing measures to mitigate the emergence and spread of antibiotic resistance and ensuring the continued availability of therapeutics for the treatment of bacterial infections.

September 2014



- 1. Slow the Emergence of Resistant Bacteria and Prevent the Spread of Resistant Infections
- 2. Strengthen National One-Health
 Surveillance Efforts to Combat Resistance
- Advance Development and Use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria
- 4. Accelerate Research to Develop New Antibiotics and Alternative Therapeutics, and Vaccines
- 5. Improve International Collaboration and Capacities for Disease Prevention and Surveillance and Antibiotic Research and Development



Thank you

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Infections

Prevented

Preventable

Prevention approach unknown

-

Need for complete implementation of practices known to prevent HAIs

Need for ongoing research to identify new strategies to prevent the remaining HAIs

AU Option – Forthcoming Changes and Upgrades

Coming soon – July 2015:

Adding 3 newly FDA approved drugs:

- Isavuconazonium (antifungal)
- Peramivir (anti-influenza)
- Ceftazidime/Avibactam (antibacterial)

Expanding NHSN AU Analysis Options:

- Ability to generate rates per single drug and selected drugs within separate antimicrobial classes

Coming later:

NHSN AU measure calculation - Enabling NHSN users to calculate their facility's Standardized Antimicrobial Administration Ratios (SAARs) in accordance with NHSN AU measure proposal specifications

CDC and States Support Hospitals Lab Testing Guidance and Capacity Building

Questions/Needs

State Public Hospital CDC Health Dept.

Guidance & Capacity Building